Want to see ALGS full AI Analyst Report?
ALGS Stock Chart & Stats
$7.47
-$0.61(-13.01%)
At close: 4:00 PM EDT
$7.47
-$0.61(-13.01%)
Day’s Range― - ―
52-Week Range$3.98 - $13.69
Previous CloseN/A
Volume203.10K
Average Volume (3M)223.79K
Market Cap
$43.15M
Enterprise Value$33.27
Total Cash (Recent Filing)$30.38M
Total Debt (Recent Filing)$3.50M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Mar 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.30
Shares Outstanding5,444,558
10 Day Avg. Volume101,329
30 Day Avg. Volume223,790
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.72
Price to Sales (P/S)42.14
P/FCF Ratio-1.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$72.50Price Target Upside870.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.55
Revenue Forecast (FY)$35.99M
Bulls Say, Bears Say
Bulls Say
Modest LeverageLow debt reduces refinancing and solvency pressure relative to many cash-burning biotech peers. This provides some financial flexibility while Aligos funds development, although it does not eliminate the need for future capital.
High Gross MarginThe high reported gross margin suggests favorable economics on existing revenue and indicates that direct costs are not the main constraint. If product or partnership revenue expands, this profile could support meaningful contribution margins.
More Controlled Equity IncentivesRemoving the evergreen provision places greater limits on automatic equity-plan expansion, potentially improving dilution discipline. Continued shareholder approval of governance and compensation matters also supports ongoing oversight as the company develops.
Bears Say
Persistent Cash BurnSubstantial recurring cash consumption shows that operations are not self-funding and that clinical development depends on external capital. Continued burn can reduce strategic flexibility and create financing or dilution risk over the next several quarters.
Deep Losses And Shrinking RevenueLarge operating and net losses combined with declining revenue indicate that the current expense base remains too high for the business scale. Without stronger revenue growth or cost reduction, profitability and sustainable cash generation remain distant.
Dependence On External FinancingThe clinical-stage model provides no established product-sales base, leaving funding dependent on equity issuance or potential partnerships. This raises execution and dilution risk because development spending must continue before commercial cash flows are available.
Aligos Therapeutics News
ALGS FAQ
What was Aligos Therapeutics’s price range in the past 12 months?
Aligos Therapeutics lowest stock price was $3.98 and its highest was $13.69 in the past 12 months.
What is Aligos Therapeutics’s market cap?
Aligos Therapeutics’s market cap is $43.15M.
When is Aligos Therapeutics’s upcoming earnings report date?
Aligos Therapeutics’s upcoming earnings report date is Mar 11, 2027 which is in 193 days.
How were Aligos Therapeutics’s earnings last quarter?
Aligos Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$1.094 by $0.954.
Is Aligos Therapeutics overvalued?
According to Wall Street analysts Aligos Therapeutics’s price is currently Undervalued.
Does Aligos Therapeutics pay dividends?
Aligos Therapeutics does not currently pay dividends.
What is Aligos Therapeutics’s EPS estimate?
Aligos Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aligos Therapeutics have?
Aligos Therapeutics has 5,444,558 shares outstanding.
What happened to Aligos Therapeutics’s price movement after its last earnings report?
Aligos Therapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$1.094. Following the earnings report the stock price went up 16.245%.
Which hedge fund is a major shareholder of Aligos Therapeutics?
Currently, no hedge funds are holding shares in ALGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aligos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.50 (870.55% Upside)
$72.50 (870.55% Upside)
Blogger Sentiment
Bullish
ALGS Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.2%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-50.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aligos Therapeutics
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
ALGS Stock 12 Month Forecast
Average Price Target
$72.50
▲(870.55% Upside)
Technical Analysis
Medicinova
―
Celularity
―
Barinthus Biotherapeutics
―
Genenta Science SpA Sponsored ADR
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
46.67%
Insiders
4.22% Mutual Funds
31.17% Other Institutional Investors
14.58% Public Companies and
Individual Investors